WY 14643A highly potent PPARα agonist

WY 14643 (CAS 50892-23-4)

WY 14643 | CAS 50892-23-4 is rated 5.0 out of 5 by 1.
  • y_2019, m_12, d_4, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.3
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203314, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 77ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: Pirinixic acid
Application: A highly potent PPARα agonist
CAS Number: 50892-23-4
Purity: ≥98%
Molecular Weight: 323.80
Molecular Formula: C14H14ClN3O2S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

WY 14643 is a highly potent PPARα agonist. Peroxisome proliferator-activated receptors (PPARs) α, β, and γ are hormone receptors that induce the gene acyl-Coa and modulate the peroxisomal beta oxidation of fatty acids. WY 14643 has been shown to inhibit TNF-α-induced VCAM-1, and reduce TNF-α and IL-1β. Studies indicate that WY 14643 inhibits proliferation of trophoblast cells at lower concentrations than clofibric acid (sc-203000), and decreases the levels of S-100 β chain (S100B) protein.


References

1. Keller, H., et al. 1993. Proc. Natl. Acad. Sci. U.S.A. 90: 2160-2164. PMID: 8384714
2. Keller, H., et al. 1993. Trends Endocrinol. Metab. 4: 291-296. PMID: 18407172
3. Tugwood, J.D., et al. 1996. Ann. N.Y. Acad. Sci. 804: 252-265. PMID: 8993548
4. Murakami, K., et al. 1999. Biochem. Biophys. Res. Commun. 260: 609-613. PMID: 10403814
5. Marx, N., et al. 1999. Circulation. 99: 3125-3131. PMID: 10377075
6. Cuzzocrea, S., et al. 2004. Shock. 22: 340-346. PMID: 15377889
7. Collino, M., et al. 2006. Free Radic. Biol. Med. 41: 579-589. PMID: 16863991
8. Hashimoto, F., et al. 2009. Biol. Pharm. Bull. 32: 1278-1282. PMID: 19571398

Physical State :
Solid
Solubility :
Soluble in DMSO (65 mg/ml at 25° C), ethanol (52 mg/ml at 25° C), DMF (~16.5 mg/ml), PBS (pH 7.2, ~0.04 mg/ml), and water (<1 mg/ml at 25° C).
Storage :
Store at room temperature
Melting Point :
199.71° C (Predicted)
Boiling Point :
~514.4° C at 760 mmHg (Predicted)
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.66 (Predicted)
IC50 :
Cyclooxygenase-1: IC50 >10 nM (sheep); Cox-2: IC50 >10 nM (human); PPARα: EC5050 = 40 nM (mouse); Aldose reductase: IC50 = 2.82 µM (rat); PPARα: IC50 = 10.11 µM (human)
Ki Data :
PPARα: Ki= 100 nM (mouse)
pK Values :
pKa: 2.99 (Predicted), pKb: 0.53 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
AG2915000
PubChem CID :
5694
MDL Number :
MFCD00191335
Beilstein Registry :
0759945
SMILES :
CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

WY 14643  Product Citations

See how others have used WY 14643. Click on the entry to view the PubMed entry .

Citations 1 to 6 of 6 total

PMID: # 29405636  Song, Z.|Revelo, X.|Shao, W.|Tian, L.|Zeng, K.|Lei, H.|Sun, HS.|Woo, M.|Winer, D.|Jin, T.| et al. 2018. Obesity (Silver Spring). 26: 547-558.

PMID: # 27967217  Zeng, K. et al. 2017. Endocrinology. 158: 277-292.

PMID: # 26819576  Zhang, X. et al. 2015. PPAR Res. 2015: 489314.

PMID: # 16912651  Yeh, CH. et al. 2006. Shock. 26: 262-270.

PMID: # 16985257  Buroker, N.E. et al. 2006. Am J Physiol Endocrinol Metab. 292: E453-E460.

PMID: # 12082115  Wang, YL. et al. 2002. J. Biol. Chem. 277: 31781-31788.

Citations 1 to 6 of 6 total

How should I store the 100mM stock solution of WY 14643 in DMSO? Can I freeze the stock solution in -20 for long term storage?

Asked by: MsMoonlight2019
Thank you for your question. We recommend storing stock solution at -20&ordm;C, and this should be used within one month.
Answered by: Technical Support
Date published: 2019-08-20
  • y_2019, m_12, d_4, h_22CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.3
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_203314, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 66ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Buroker Buroker, N.E. et al. (PubMed 16985257) used WY 14643, a potent PPAR agonist, to determine if there were any interactions between PPAR and thyroid hormone receptors in the heart. Introduction of WY 14643 induced a twofold increase in gene expression of the reporter UCP3, indicating a novel interaction between PPAR and thyroid hormone receptors. -SCBT Publication Review
Date published: 2015-03-04
  • y_2019, m_12, d_4, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.3
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203314, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 4ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.